News
Medochemie earns its 9th 'Export Award'
Medochemie Ltd, was honoured for the 9th time by the Exports Awards Committee of the Cyprus Chamber of Commerce and Industry, with the 'Export Award' that applies for large companies (with over 50 employees). Medochemie Ltd manufactures quality pharmaceutical products at reasonable prices for people all over the world, working under the current Good Manufacturing Practice (cGMP) regulations of the European Union and of the World Health Organisation (WHO). Medochemie Ltd provides the opportunity to more than 150 million people to access medication and get the pharmaceutical treatment they need. In the last two years, the company has significantly expanded its business by providing medicines that are manufactured in Cyprus to many new European markets, including Germany, France, Austria, England, Italy, and Spain, as well as to Australia, and Japan, and many other countries, using strategically planned partnerships, as well as growth in developing countries with a future growth potential in the generic pharmaceutical business.
Medochemie Ltd, was honoured for the 9th time by the Exports Awards Committee of the Cyprus Chamber of Commerce and Industry, with the 'Export Award' that applies for large companies (with over 50 employees). Medochemie Ltd manufactures quality pharmaceutical products at reasonable prices for people all over the world, working under the current Good Manufacturing Practice (cGMP) regulations of the European Union and of the World Health Organisation (WHO). Medochemie Ltd provides the opportunity to more than 150 million people to access medication and get the pharmaceutical treatment they need. In the last two years, the company has significantly expanded its business by providing medicines that are manufactured in Cyprus to many new European markets, including Germany, France, Austria, England, Italy, and Spain, as well as to Australia, and Japan, and many other countries, using strategically planned partnerships, as well as growth in developing countries with a future growth potential in the generic pharmaceutical business.
